Page 66 - Read Online

Page 12 of 13 Farkas et al. J Cancer Metastasis Treat 2022;8:37 https://dx.doi.org/10.20517/2394-4722.2022.89

biopsy-heavy setting: an external validation study of 563 cases. Am J Surg Pathol 2020;44:347-56. DOI PubMed
25. Fuchs TL, Chou A, Aksoy Y, et al. A critical assessment of current grading schemes for diffuse pleural mesothelioma with a proposal
for a novel mesothelioma weighted grading scheme (MWGS). Am J Surg Pathol 2022;46:774-85. DOI PubMed
26. Marchevsky AM, LeStang N, Hiroshima K, et al. The differential diagnosis between pleural sarcomatoid mesothelioma and spindle
cell/pleomorphic (sarcomatoid) carcinomas of the lung: evidence-based guidelines from the International Mesothelioma Panel and the
MESOPATH National Reference Center. Hum Pathol 2017;67:160-8. DOI PubMed
27. Le Stang N, Burke L, Blaizot G, et al. Differential diagnosis of epithelioid malignant mesothelioma with lung and breast pleural
metastasis: a systematic review compared with a standardized panel of antibodies-a new proposal that may influence pathologic
practice. Arch Pathol Lab Med 2020;144:446-56. DOI PubMed
28. Chapel DB, Schulte JJ, Husain AN, Krausz T. Application of immunohistochemistry in diagnosis and management of malignant
mesothelioma. Transl Lung Cancer Res 2020;9:S3-S27. DOI PubMed PMC
29. Ordóñez NG. The immunohistochemical diagnosis of mesothelioma: a comparative study of epithelioid mesothelioma and lung
adenocarcinoma. Am J Surg Pathol 2003;27:1031-51. DOI PubMed
30. Ordóñez NG. Application of immunohistochemistry in the diagnosis of epithelioid mesothelioma: a review and update. Hum Pathol
2013;44:1-19. DOI PubMed
31. Patel A, Borczuk AC, Siddiqui MT. Utility of claudin-4 versus BerEP4 and B72.3 in pleural fluids with metastatic lung
adenocarcinoma. J Am Soc Cytopathol 2020;9:146-51. DOI PubMed
32. Vojtek M, Walsh MD, Papadimos DJ, Shield PW. Claudin-4 immunohistochemistry is a useful pan-carcinoma marker for serous
effusion specimens. Cytopathology 2019;30:614-9. DOI PubMed
33. Naso JR, Churg A. Claudin-4 shows superior specificity for mesothelioma vs non-small-cell lung carcinoma compared with MOC-31
and Ber-EP4. Hum Pathol 2020;100:10-4. DOI PubMed
34. McGregor SM, Dunning R, Hyjek E, Vigneswaran W, Husain AN, Krausz T. BAP1 facilitates diagnostic objectivity, classification,
and prognostication in malignant pleural mesothelioma. Hum Pathol 2015;46:1670-8. DOI PubMed
35. Hakim SA, Abou Gabal HH. Diagnostic utility of BAP1, EZH2 and survivin in differentiating pleural epithelioid mesothelioma and
reactive mesothelial hyperplasia: immunohistochemical study. Pathol Oncol Res 2021;27:600073. DOI PubMed PMC
36. Chapel DB, Hornick JL, Barlow J, Bueno R, Sholl LM. Clinical and molecular validation of BAP1, MTAP, P53, and Merlin
immunohistochemistry in diagnosis of pleural mesothelioma. Mod Pathol 2022. DOI PubMed
37. Dagogo-Jack I, Madison RW, Lennerz JK, et al. Molecular characterization of mesothelioma: impact of histologic type and site of
origin on molecular landscape. JCO Precis Oncol 2022;6:e2100422. DOI PubMed
38. Hung YP, Dong F, Torre M, Crum CP, Bueno R, Chirieac LR. Molecular characterization of diffuse malignant peritoneal
mesothelioma. Mod Pathol 2020;33:2269-79. DOI PubMed
39. Marshall K, Jackson S, Jones J, et al. Homozygous deletion of CDKN2A in malignant mesothelioma: diagnostic utility, patient
characteristics and survival in a UK mesothelioma centre. Lung Cancer 2020;150:195-200. DOI PubMed
40. Oyama Y, Hamasaki M, Matsumoto S, Sato A, Tsujimura T, Nabeshima K. Short 57 kb. CDKN2A ;22:813. DOI PubMed PMC
41. Nabeshima K, Hamasaki M, Kinoshita Y, Matsumoto S, Sa-Ngiamwibool P. Update of pathological diagnosis of pleural mesothelioma
using genomic-based morphological techniques, for both histological and cytological investigations. Pathol Int 2022;72:389-401. DOI
PubMed
42. Chapel DB, Dubuc AM, Hornick JL, Sholl LM. Correlation of methylthioadenosine phosphorylase (MTAP) protein expression with
MTAP and CDKN2A copy number in malignant pleural mesothelioma. Histopathology 2021;78:1032-42. DOI PubMed
43. Illei PB, Rusch VW, Zakowski MF, Ladanyi M. Homozygous deletion of CDKN2A and codeletion of the methylthioadenosine
phosphorylase gene in the majority of pleural mesotheliomas. Clin Cancer Res 2003;9:2108-13. PubMed
44. Brcic L, Le Stang N, Gallob F, et al. A combination of MTAP and p16 immunohistochemistry can substitute for CDKN2A
fluorescence In situ hybridization in diagnosis and prognosis of pleural mesotheliomas. Arch Pathol Lab Med 2022. DOI PubMed
45. Hwang HC, Sheffield BS, Rodriguez S, et al. Utility of BAP1 immunohistochemistry and p16 (CDKN2A) fish in the diagnosis of
malignant mesothelioma in effusion cytology specimens. Am J Surg Pathol 2016;40:120-6. DOI PubMed
46. Berg KB, Dacic S, Miller C, Cheung S, Churg A. Utility of methylthioadenosine phosphorylase compared with BAP1
immunohistochemistry, and CDKN2A and NF2 fluorescence in situ hybridization in separating reactive mesothelial proliferations
from epithelioid malignant mesotheliomas. Arch Pathol Lab Med 2018;142:1549-53. DOI PubMed
47. Kinoshita Y, Hida T, Hamasaki M, et al. A combination of MTAP and BAP1 immunohistochemistry in pleural effusion cytology for
the diagnosis of mesothelioma. Cancer Cytopathol 2018;126:54-63. DOI PubMed
48. Naso JR, Tessier-Cloutier B, Senz J, Huntsman DG, Churg A. Significance of p53 immunostaining in mesothelial proliferations and
correlation with TP53 mutation status. Mod Pathol 2022;35:77-81. DOI PubMed
49. Terra S, Roden AC, Yi ES, Aubry MC, Boland JM. Loss of methylthioadenosine phosphorylase by immunohistochemistry is common
in pulmonary sarcomatoid carcinoma and sarcomatoid mesothelioma. Am J Clin Pathol 2022;157:33-9. DOI PubMed
50. Andrici J, Sheen A, Sioson L, et al. Loss of expression of BAP1 is a useful adjunct, which strongly supports the diagnosis of
mesothelioma in effusion cytology. Mod Pathol 2015;28:1360-8. DOI PubMed PMC
51. Sheffield BS, Hwang HC, Lee AF, et al. BAP1 immunohistochemistry and p16 FISH to separate benign from malignant mesothelial
proliferations. Am J Surg Pathol 2015;39:977-82. DOI PubMed
52. Soeberg MJ, Creighton N, Currow DC, Young JM, van Zandwijk N. Patterns in the incidence, mortality and survival of malignant